BC Week In Review | Oct 24, 2016
Clinical News

CX1739: Preliminary Phase IIa data

In September, RespireRx reported preliminary data from 15 patients who achieved >25% depression of their respiratory rate following an acute IV bolus injection of 1ug/kg remifentanil in the double-blind Stage 1 of a 2-stage, crossover,...
BC Week In Review | Mar 7, 2016
Clinical News

CX1739: Phase IIa start

This month, RespireRx will begin a double-blind, placebo-controlled, dose-escalation, U.S. Phase IIa trial to evaluate 3 dose levels of oral CX1739 in about 18 patients. RespireRx Pharmaceuticals Inc. (OTCQB:RSPI), Glen Rock, N.J.   Product: CX1739...
BC Innovations | Feb 5, 2015
Product R&D

Addex's allosterics

Allosteric modulators are slowly filling the clinical pipeline, but finding the right assays to discover and characterize them properly still confounds companies in the space. Addex Therapeutics Ltd. is going back to basics and forging...
BC Week In Review | Jul 14, 2014
Company News

Cortex Pharmaceuticals Inc, University of Illinois deal

Cortex received exclusive, worldwide rights from the university to patents covering the use of cannabinoids to treat sleep-related breathing disorders. Cortex’s dronabinol, a cannabinol agonist, is in a Phase II trial conducted by the university...
BioCentury | Oct 15, 2012
Strategy

At home with Servier

Rather than follow in the footsteps of other foundation-backed mid-size European pharmas that have largely concentrated on a single therapeutic area and looked to new markets for growth, Servier has determined its path to sustainability...
BC Week In Review | Aug 20, 2012
Company News

Cortex Pharmaceuticals, Pier Pharmaceuticals deal

Cortex merged with Pier in a stock deal. Pier's former shareholders and vendors received about 58 million Cortex common shares, which are valued at about $4.1 million based on Cortex's close of $0.07 on Aug....
BC Week In Review | Jul 2, 2012
Financial News

Cortex Pharmaceuticals completes private placement of notes and warrants

Cortex Pharmaceuticals Inc. (OTCBB:CORX), Irvine, Calif.   Business: Neurology   Date completed: 6/26/12   Type: Private placement of notes and warrants   Raised: $400,000   Investor: Samyang Optics   Note: The secured promissory note bears...
BC Week In Review | Oct 31, 2011
Financial News

Cortex Pharmaceuticals Inc completes private placement of common stock and warrants

Cortex Pharmaceuticals Inc . (OTCBB:CORX), Irvine, Calif.   Business: Neurology   Date completed: 10/26/11   Type: Private placement of common stock and warrants   Raised: $500,000   Shares: 6.8 million   Price: $0.07   Shares after...
BC Week In Review | Oct 31, 2011
Company News

Cortex Pharmaceuticals, Samyang Optics Co. Ltd. deal

The parties signed a memorandum of understanding granting Samyang South Korean rights to CX1739 for neurodegenerative diseases. Samyang will also receive the right of negotiation for rights to CX1846 for neurodegenerative diseases as well as...
BC Week In Review | Oct 10, 2011
Company News

Cortex Pharmaceuticals, Servier deal

Servier exercised an option from Cortex to license exclusive, worldwide rights to develop and commercialize CX1632 . Cortex will receive $2 million up front, and is eligible for milestones and royalties. Servier paid Cortex $1 million...
Items per page:
1 - 10 of 147
BC Week In Review | Oct 24, 2016
Clinical News

CX1739: Preliminary Phase IIa data

In September, RespireRx reported preliminary data from 15 patients who achieved >25% depression of their respiratory rate following an acute IV bolus injection of 1ug/kg remifentanil in the double-blind Stage 1 of a 2-stage, crossover,...
BC Week In Review | Mar 7, 2016
Clinical News

CX1739: Phase IIa start

This month, RespireRx will begin a double-blind, placebo-controlled, dose-escalation, U.S. Phase IIa trial to evaluate 3 dose levels of oral CX1739 in about 18 patients. RespireRx Pharmaceuticals Inc. (OTCQB:RSPI), Glen Rock, N.J.   Product: CX1739...
BC Innovations | Feb 5, 2015
Product R&D

Addex's allosterics

Allosteric modulators are slowly filling the clinical pipeline, but finding the right assays to discover and characterize them properly still confounds companies in the space. Addex Therapeutics Ltd. is going back to basics and forging...
BC Week In Review | Jul 14, 2014
Company News

Cortex Pharmaceuticals Inc, University of Illinois deal

Cortex received exclusive, worldwide rights from the university to patents covering the use of cannabinoids to treat sleep-related breathing disorders. Cortex’s dronabinol, a cannabinol agonist, is in a Phase II trial conducted by the university...
BioCentury | Oct 15, 2012
Strategy

At home with Servier

Rather than follow in the footsteps of other foundation-backed mid-size European pharmas that have largely concentrated on a single therapeutic area and looked to new markets for growth, Servier has determined its path to sustainability...
BC Week In Review | Aug 20, 2012
Company News

Cortex Pharmaceuticals, Pier Pharmaceuticals deal

Cortex merged with Pier in a stock deal. Pier's former shareholders and vendors received about 58 million Cortex common shares, which are valued at about $4.1 million based on Cortex's close of $0.07 on Aug....
BC Week In Review | Jul 2, 2012
Financial News

Cortex Pharmaceuticals completes private placement of notes and warrants

Cortex Pharmaceuticals Inc. (OTCBB:CORX), Irvine, Calif.   Business: Neurology   Date completed: 6/26/12   Type: Private placement of notes and warrants   Raised: $400,000   Investor: Samyang Optics   Note: The secured promissory note bears...
BC Week In Review | Oct 31, 2011
Financial News

Cortex Pharmaceuticals Inc completes private placement of common stock and warrants

Cortex Pharmaceuticals Inc . (OTCBB:CORX), Irvine, Calif.   Business: Neurology   Date completed: 10/26/11   Type: Private placement of common stock and warrants   Raised: $500,000   Shares: 6.8 million   Price: $0.07   Shares after...
BC Week In Review | Oct 31, 2011
Company News

Cortex Pharmaceuticals, Samyang Optics Co. Ltd. deal

The parties signed a memorandum of understanding granting Samyang South Korean rights to CX1739 for neurodegenerative diseases. Samyang will also receive the right of negotiation for rights to CX1846 for neurodegenerative diseases as well as...
BC Week In Review | Oct 10, 2011
Company News

Cortex Pharmaceuticals, Servier deal

Servier exercised an option from Cortex to license exclusive, worldwide rights to develop and commercialize CX1632 . Cortex will receive $2 million up front, and is eligible for milestones and royalties. Servier paid Cortex $1 million...
Items per page:
1 - 10 of 147